Preliminary comparison of normalized T1 and non-contrast perfusion MRI assessments of regional lung disease in cystic fibrosis patients

Shannon Donnola(University Hospitals Cleveland Medical Center), Chris A. Flask(Case Western Reserve University), A V Prabhakaran(Lake Forest Academy), Kimberly McBennett(Rainbow Babies & Children's Hospital), Mitchell L. Drumm(University School), James F. Chmiel(Riley Hospital for Children), Elliott C. Dasenbrook(Cleveland Clinic), Xin Yu, Lan Lŭ(Cleveland Clinic), Karishma Gupta(Case Western Reserve University), David Weaver(University Hospitals Cleveland Medical Center), Michael W. Konstan(Case Western Reserve University)
Journal of Cystic Fibrosis
December 22, 2015
10.1016/j.jcf.2015.11.009
Cited by 18

Related Papers

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
|New England Journal of Medicine|2011|870
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation
|Thorax|2011|501
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
|The Lancet Respiratory Medicine|2014|442